secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOTRICITY INC. (BTCY)
CIK:        0001630113
Form:       8-K
Filed at:   2026-02-18T23:59:59+00:00
Accession:  0001493152-26-007369
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biotricity Q3 FY26 revenue up 10% to $4M; net loss narrows 13% to $1.1M
-----------------------------------------------------------------------

- Revenue $4M (+10.2% YoY); gross margin expanded to 81.5% from 76.4%.
- Net loss $1.1M ($0.042 per share) vs $1.3M ($0.054 per share) prior year.
- Third consecutive quarter of positive EBITDA and net operating income.
- Recurring TaaS revenue $3.6M (91.2% of total); customer retention 90%+.
- FDA clearance for AI clinical model expected in coming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630113/000149315226007369/0001493152-26-007369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630113/000149315226007369/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer